Researchers from the UCLA Health Jonsson Comprehensive Cancer Center have demonstrated in a recent study that their novel non ...

A recent study conducted by UCLA Health Jonsson Comprehensive Cancer Center researchers found that new, non-invasive imaging ...

HAYWARD, CA, USA I October 02, 2024 I Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing ...

A recent study conducted by UCLA Health Jonsson Comprehensive Cancer Center researchers found that new, non-invasive imaging ...

A new study led by investigators from the UCLA Health Jonsson Comprehensive Cancer Center has demonstrated a new, non-invasive imaging technique can accurately detect clear-cell renal cell carcinoma, ...

UCLA Health researchers unveiled a novel non-invasive imaging technique that accurately detects clear-cell renal cell ...

No benefit seen for rechallenge with nivolumab after progression in the post-immune checkpoint inhibitor setting.

Arcus Biosciences has announced a clinical trial partnership with AstraZeneca to assess the combination of casdatifan (AB521) ...

Wednesday announced a clinical trial collaboration agreement with AstraZeneca (AZN) to evaluate casdatifan in combination with volrustomig for the treatment of clear cell renal cell carcinoma or ccRCC ...

Genenta Science (NASDAQ: GNTA), a pioneer in immuno-oncology and a leader in cell-based therapeutics, is pleased to announce that the Agenzia Italiana del Farmaco (AIFA) has approved a new Phase 1 ...

Toni Choueiri, MD, discusses the rationale behind the drug combination of tivozanib and nivolumab in the TiNivo-2 study.